Wellous Pharma Private Limited - Due diligence report

A 360° intelligence report on Wellous Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and …

2016-10-04 Villupuram, Tamil Nadu Active Unlisted Active Compliant
Share
WP Wellous Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Wellous Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
85/100
Trust Score
Low Risk

Wellous Pharma Private Limited is assessed as Low Risk with a Trust Score of 85/100. Wellous Pharma Private Limited is an active private limited indian non-government company incorporated in 2016, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 19 Jul 2026 from the latest processed filings. Wellous Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
85/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.

Charges position: 1 open (5.29 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Indian Bank1 48.0 cr
Compliance Score: 86/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 2 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 85/100
NameDIN / PANDesignationAppointedTenureDIN status
RAMESH NARAYANA IYENGAR 01234567 Director 01/04/2018 6 yrs Approved
BHARAT BUSHAN VRASHABA DOSS 01234567 Director 01/04/2018 6 yrs Approved
KARUNAKARAN 01234567 Director 01/04/2018 6 yrs Approved
SRIVATSAN MURALI 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • 2 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 90 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
Operating for 9 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence87/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment64/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 5.29 cr already registered.
  • Compliance record supports lending.
Investor view85/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 14 events
30 Sep 2025
Last AGM held
Annual general meeting
10 Jun 2025
Director appointed
RAMESH NARAYANA IYENGAR (Director)
Director appointed
SRIVATSAN MURALI (Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Nov 2024
Director ceased
VENKATESAN THULASI CHETTIAR GOVINDAN
29 Sep 2023
Director ceased
BHARAT BUSHAN VRASHABA DOSS
10 Oct 2022
Director appointed
BHARAT BUSHAN VRASHABA DOSS (Director)
31 Mar 2022
Share transfer (FY 2022)
300000.00000000 shares to ARUNACHALAM KARUNAKARAN
31 Mar 2021
Share transfer (FY 2021)
287400.00000000 shares to ARUNACHALAM KARUNAKARAN
31 Mar 2018
Securities allotted
1527300 Equity Shares - 1.53 cr raised
06 Nov 2017
Charge created
Indian Bank - 5.29 cr
31 Mar 2017
Securities allotted
4370100 Equity Shares - 4.37 cr raised
04 Oct 2016
Incorporated
Registered with Roc Chennai
Director appointed
KARUNAKARAN (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Ronald Pharmaceutical U24110GJ1993PTC019347 Baroda, Gujarat, India
Brassica Pharma Private Limited U24230MH2006PTC160053 Mumbai, Maharashtra, India
Krushinath Green Energy Limited U15421PN2012PLC142602 Pune, Maharashtra, India
Casper Pharma U24233MH2016PTC423891 Mumbai, Maharashtra, India
Pragati Aroma Oil Distillers P Ltd U29299MH1989PTC053946 Mumbai, Maharashtra, India
Capsoft Healthcare Private Limited U74999HP2020PTC007952 Baddi, Himachal Pradesh, India
Gmk Labs Private Limited U24239TG2006PTC051554 Secunderabad, Telangana, India
Linux Life Sciences U74900PY2015PTC002951 Pondicherry, Pondicherry, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Wellous Pharma Private Limited before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Wellous Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Wellous Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 85/100, distress signals and MSME payment-delay disclosures - know whether Wellous Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Wellous Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Wellous Pharma Private Limited an active company?

Wellous Pharma Private Limited has MCA status “Active” with a compliance score of 86/100 (Low Risk).

Is Wellous Pharma Private Limited financially healthy?

Wellous Pharma Private Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Wellous Pharma Private Limited?

Its overall Trust Score is 85/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Wellous Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Wellous Pharma Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Wellous Pharma Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).

Is it risky to lend to Wellous Pharma Private Limited?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.